JP2005519091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519091A5 JP2005519091A5 JP2003572444A JP2003572444A JP2005519091A5 JP 2005519091 A5 JP2005519091 A5 JP 2005519091A5 JP 2003572444 A JP2003572444 A JP 2003572444A JP 2003572444 A JP2003572444 A JP 2003572444A JP 2005519091 A5 JP2005519091 A5 JP 2005519091A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cancer
- herpesvirus
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 7
- 241001529453 unidentified herpesvirus Species 0.000 claims 7
- 238000002271 resection Methods 0.000 claims 3
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36113202P | 2002-03-01 | 2002-03-01 | |
| PCT/US2003/006519 WO2003073918A2 (en) | 2002-03-01 | 2003-03-03 | Prevention of recurrence and metastasis of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519091A JP2005519091A (ja) | 2005-06-30 |
| JP2005519091A5 true JP2005519091A5 (enExample) | 2006-04-20 |
Family
ID=27789076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572444A Pending JP2005519091A (ja) | 2002-03-01 | 2003-03-03 | 癌の再発及び転移の予防 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050255085A1 (enExample) |
| EP (1) | EP1487983A4 (enExample) |
| JP (1) | JP2005519091A (enExample) |
| AU (1) | AU2003216502B2 (enExample) |
| CA (1) | CA2476724A1 (enExample) |
| WO (1) | WO2003073918A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| GB0326798D0 (en) * | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| JP2005336094A (ja) * | 2004-05-26 | 2005-12-08 | Akikimi Nakao | 変異単純ヘルペスウイルスからなる転移性乳癌および再発性乳癌の治療剤 |
| US8986672B2 (en) * | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| JP6588024B2 (ja) | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| EP3377637B1 (en) * | 2016-04-08 | 2020-03-18 | Krystal Biotech, LLC | Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin |
| WO2017189754A1 (en) * | 2016-04-26 | 2017-11-02 | Salk Institute For Biological Studies | Hsv--1 oncolytic virus therapies that specificallyh kill alt dependent cancers |
| KR20200042904A (ko) | 2017-07-26 | 2020-04-24 | 온코루스, 인크. | 종양용해성 바이러스 벡터 및 그의 용도 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| JP2024513826A (ja) | 2021-04-02 | 2024-03-27 | クリスタル バイオテック インコーポレイテッド | がん治療のためのウイルスベクター |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162231A (en) * | 1989-10-25 | 1992-11-10 | Cole Dean A | Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung |
| US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) * | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| EP0675961B1 (en) * | 1992-03-31 | 2002-11-27 | Arch Development Corporation | Treatment of tumorigenic disease with a modified HSV |
| US20020010144A1 (en) * | 1994-04-29 | 2002-01-24 | Robert Sobol | Enhancing the sensitivity of tumor cells to therapies |
| US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US6139834A (en) * | 1994-06-23 | 2000-10-31 | Georgetown University | Replication-competent Herpes simplex virus mediates destruction of neplastic cells |
| US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US6406861B1 (en) * | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
| WO2000045853A2 (en) * | 1999-02-05 | 2000-08-10 | Arch Development Corporation | Treatment of tumors with genetically engineered herpes virus |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) * | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| US7064111B1 (en) * | 1999-10-05 | 2006-06-20 | Georgetown University | Use of soluble costimulatory factor for tumor immuno-gene therapy |
| AU6814601A (en) * | 2000-06-01 | 2001-12-11 | Sloan Kettering Inst Cancer | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| JP4212897B2 (ja) * | 2001-03-27 | 2009-01-21 | 具紀 藤堂 | ウイルスおよび治療法におけるそれらの使用 |
-
2003
- 2003-03-03 JP JP2003572444A patent/JP2005519091A/ja active Pending
- 2003-03-03 AU AU2003216502A patent/AU2003216502B2/en not_active Ceased
- 2003-03-03 CA CA002476724A patent/CA2476724A1/en not_active Abandoned
- 2003-03-03 WO PCT/US2003/006519 patent/WO2003073918A2/en not_active Ceased
- 2003-03-03 EP EP03743747A patent/EP1487983A4/en not_active Withdrawn
- 2003-03-03 US US10/505,375 patent/US20050255085A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Cancer treatment evolution from traditional methods to stem cells and gene therapy | |
| Serša et al. | Electrochemotherapy: variable anti-tumor effect on different tumor models | |
| Li et al. | Cytokine and immuno-gene therapy for solid tumors | |
| JP2005519091A5 (enExample) | ||
| JP2017506662A5 (enExample) | ||
| Yun et al. | Convection‐Enhanced Delivery for Targeted Delivery of Antiglioma Agents: The Translational Experience | |
| Menezes et al. | Prospects of gene therapy to treat melanoma | |
| JP3309990B2 (ja) | 生物学的応答調節剤としての双性イオンの組成物及び方法 | |
| CN118286421A (zh) | 用作治疗性疫苗的纳米粒子 | |
| Hou et al. | Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation | |
| Schirrmacher et al. | Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies | |
| Zhao et al. | The role of mesenchymal stem cells in cancer immunotherapy | |
| WO2010026638A1 (ja) | 抗制御性ｔ細胞抗体と磁性微粒子を含む悪性腫瘍の温熱治療用キット、及びその温熱治療法 | |
| KR20070008710A (ko) | 바이러스 및 캄토테신을 이용한 암치료 방법 | |
| CN116271054A (zh) | 一种工程化髓样细胞及其制备方法和用途 | |
| Lan et al. | Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells 2021, 10, 100 | |
| Hashimura et al. | Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor | |
| Rubin et al. | Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer | |
| TR2022020067A2 (tr) | Sars cov-2 vi̇rüsünün melanoma tedavi̇si̇nde kullanimi | |
| Wang et al. | Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors | |
| Lu | Evaluation of viral therapy for cancer treatment | |
| WO2004087208A1 (ja) | 熱ショックタンパク質と磁性微粒子からなる悪性腫瘍の温熱治療剤 | |
| Bossow et al. | 832. Intrapleural Administration of Third Generation Oncolytic HSV-1 (G47∆) Is Highly Efficacious in Orthotopic Malignant Pleural Mesothelioma Models | |
| Mccray et al. | 948. Regression of Established Melanoma Tumors through Intratumoral Delivery of HIV-1 Vpr Using In Vivo Electroporation | |
| Tsuno et al. | 480. STAT3-Inactivated Dendritic Cell Vaccination Could Induce Stronger Anti-Tumor Immune Responses |